Status:
COMPLETED
Transrectal Tumour Oxygen - US Army
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
U.S. Army Medical Research and Development Command
Princess Margaret Hospital, Canada
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
18-80 years
Phase:
PHASE2
Brief Summary
Prostate cancer is now the most commonly diagnosed tumor among men in the United States. Most patients have tumors that are confined to the prostate gland at diagnosis and are suitable for treatment w...
Eligibility Criteria
Inclusion
- A histologic diagnosis of adenocarcinoma of the prostate
- A decision to treat using high-dose conformal radiotherapy, with or without neoadjuvant and concurrent androgen ablation
- Clinical stage T2a or T2b, N0, M0 (UICC 1997 68)
- No hormonal or cytotoxic anti-cancer therapy prior to study entry
- ECOG performance status of 2 or less
- Ability to understand the English language
- Signed informed consent
Exclusion
- Patients with prior or active malignancy within 5 years of the diagnosis of prostate cancer, except non-melanoma skin cancer
Key Trial Info
Start Date :
January 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2023
Estimated Enrollment :
195 Patients enrolled
Trial Details
Trial ID
NCT00160979
Start Date
January 1 2001
End Date
February 1 2023
Last Update
June 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9